Share on StockTwits

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) gapped up prior to trading on Wednesday after Leerink Swann raised their price target on the stock from $171.00 to $177.00, AnalystRatingsNetwork reports. The stock had previously closed at $139.91, but opened at $140.10. Leerink Swann currently has an outperform rating on the stock. Jazz Pharmaceuticals plc – shares last traded at $141.93, with a volume of 260,823 shares trading hands.

A number of other firms have also recently commented on JAZZ. Analysts at Buckingham Research initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, July 23rd. They set a “buy” rating and a $215.00 price target on the stock. Separately, analysts at Deutsche Bank initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, July 22nd. They set a “buy” rating and a $176.00 price target on the stock. Finally, analysts at SunTrust initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, July 16th. They set a “neutral” rating and a $158.00 price target on the stock. Six investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $171.67.

The stock has a 50-day moving average of $148.3 and a 200-day moving average of $145.8. The company has a market cap of $8.397 billion and a P/E ratio of 106.54.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its earnings data on Thursday, May 8th. The company reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter in the previous year, the company posted $1.37 earnings per share. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc – will post $8.07 EPS for the current fiscal year.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.